Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

  • Technology appraisal guidance
  • TA387
  • Published: 
  • Last updated: 

History

Documents created during the development process.

Expected publication

Final appraisal determination: 2

Draft guidance: 2

Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone): final appraisal determination

Appraisal consultation

Prostate cancer (metastatic, castrate-resistant, not treated with chemotherapy) - abiraterone acetate (with prednisolone): letter to consultees about suspension of appraisal

Prostate cancer (metastatic, castrate-resistant, not treated with chemotherapy) - abiraterone acetate (with prednisolone): Appendix B - final scope

Prostate cancer (metastatic, castrate-resistant, not treated with chemotherapy) - abiraterone acetate (with prednisolone): Appendix C - final matrix

Prostate cancer (metastatic, castrate-resistant, not treated with chemotherapy) - abiraterone acetate (with prednisolone): Appendix D - response to comments on the draft scope and provisional matrix

Prostate cancer (metastatic, castrate-resistant, not treated with chemotherapy) - abiraterone acetate (with prednisolone): EIA form - scoping

Appendix B - draft scope for consultation (pre-referral) - July 2011

Appendix C - provisional matrix (pre-referral) - July 2011